NNLX - NanoLogix, Incorporated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNLX - NanoLogix, Incorporated

NNLX 0.0001000

0.0%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: kphone	4/28/2017 12:06:26 PM
	of 78

NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego: ? ? NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session. ?NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates. The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. ?The published research results may be accessed through this link: http://dx.doi.org/10.1155/2016/5293034? The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method. Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link: *https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo* The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here: https://www.asm.org/index.php/asm-microbe-2017?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next